Quantcast

Industry news that matters to you.  Learn more

EntreMed Announces Initiation Of Second Site For Phase 2 Trial In Triple-Negative Breast Cancer

EntreMed, Inc. (ENMD), a clinical-stage pharmaceutical company, recently announced the initiation of a second site for its Phase 2 study of ENMD-2076 in triple-negative breast cancer (TNBC). Kathy Miller, MD, Associate Professor at the Melvin and Bren Simon Cancer Center at Indiana University serves as the investigator for the study. Indiana University joins the University of Colorado Cancer Center where the Phase 2 study is already underway. This study is sponsored by EntreMed and is supported by a grant from the National Cancer Institute. More information about the clinical trial can be found at www.ClinicalTrials.gov.

University of Colorado Cancer Center Test Cited in Helping to Reduce Deaths in Clinical Trial

Researchers at the University of Colorado Cancer Center have developed a test that identifies key biomarkers in advanced lung cancer that helped reduce the risk of death by 36 percent over a 30-month period in a recent clinical trial.

Cancer Biomarker Study Data Presented at the 2011 AACR Meeting

A roundup of five research studies on cancer biomarkers that were presented earlier this week at the American Association for Cancer Research (AACR) 102nd Annual Meeting in Orlando, Florida.